Press Release Archives - Biologics by McKesson

InspiroGene by McKesson Partners with Vertex to Expand Distribution Options for CASGEVY® (exagamglogene autotemcel)

Nov 14, 2024 | Press Release

We are thrilled to announce a pivotal milestone for Biologics. As of today, we’ve gained access to our first gene therapy, Casgevy. CASGEVY is a one-time gene therapy that may help people 12 years and older with sickle cell disease (SCD) and frequent vaso-occlusive...

VORANIGO (vorasidenib), FDA Approved for the Treatment of Patients with IDH-mutant Diffuse Glioma, Available at Biologics by McKesson

Sep 25, 2024 | Press Release

CARY, N.C., September 25, 2024—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease, was selected by Servier as a limited specialty pharmacy provider for VORANIGO (vorasidenib) for the treatment of adult and pediatric...

ZOKINVY (lonafarnib), the only FDA Approved Treatment for Hutchinson-Gilford Progeria Syndrome, Now Exclusively Available at Biologics by McKesson

Sep 10, 2024 | Press Release

CARY, N.C., September 10, 2024 –Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease, was selected by Sentynl Therapeutics, Inc., as the exclusive specialty pharmacy for ZOKINVY® (lonafarnib) in the United States. ZOKINVY...

RYTELO (imetelstat), FDA Approved for Treatment of Patients with Low- to Intermediate-1 Risk Myelodysplastic Syndromes (MDS) with Transfusion-dependent Anemia, Available at Biologics by McKesson

Sep 9, 2024 | Press Release

CARY, N.C., September 9, 2024—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Geron Corporation as a limited specialty pharmacy provider for RYTELO™ (imetelstat) for the treatment of adult...

CAMCEVI® (leuprolide) 42mg injection emulsion, FDA Approved for Treatment of Advanced Prostate Cancer, Available Exclusively at Biologics by McKesson

Jun 19, 2024 | Press Release

CARY, N.C., June 19, 2024—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Accord BioPharma, Inc. as an exclusive specialty pharmacy provider for CAMCEVI (leuprolide) 42mg injection...

OJEMDA (tovorafenib), FDA Approved for Pediatric Low-Grade Glioma, Available at Biologics by McKesson

Apr 23, 2024 | Press Release

CARY, N.C., April 23, 2024 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease, was selected by Day One Biopharmaceuticals, as a limited network specialty pharmacy for OJEMDA™ (tovorafenib) for the treatment of...

« Older Entries